In kitten ventricular myocardium, the inotropic potency of an agonist is determined by both its intrinsic activity for the adenylyl cyclase and its affinity for the beta-adrenoceptors.
D000262:Adenylyl Cyclases / Q000378:metabolism*; D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000818:Animals; D002046:Bupranolol / Q000494:pharmacology; D002415:Cats; D006321:Heart / Q000187:drug effects*; D066298:In Vitro Techniques; D008566:Membranes / Q000187:drug effects; D009200:Myocardial Contraction / Q000187:drug effects; D009206:Myocardium / Q000201:enzymology; D010210:Papillary Muscles / Q000187:drug effects; D011941:Receptors, Adrenergic / Q000187:drug effects*; D011943:Receptors, Adrenergic, beta / Q000187:drug effects*
D000318:Adrenergic beta-Agonists; D011941:Receptors, Adrenergic; D011943:Receptors, Adrenergic, beta; D002046:Bupranolol; D000262:Adenylyl Cyclases